Literature DB >> 12508119

Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation.

Hong Wang1, Man Yu, Mahendar Ochani, Carol Ann Amella, Mahira Tanovic, Seenu Susarla, Jian Hua Li, Haichao Wang, Huan Yang, Luis Ulloa, Yousef Al-Abed, Christopher J Czura, Kevin J Tracey.   

Abstract

Excessive inflammation and tumour-necrosis factor (TNF) synthesis cause morbidity and mortality in diverse human diseases including endotoxaemia, sepsis, rheumatoid arthritis and inflammatory bowel disease. Highly conserved, endogenous mechanisms normally regulate the magnitude of innate immune responses and prevent excessive inflammation. The nervous system, through the vagus nerve, can inhibit significantly and rapidly the release of macrophage TNF, and attenuate systemic inflammatory responses. This physiological mechanism, termed the 'cholinergic anti-inflammatory pathway' has major implications in immunology and in therapeutics; however, the identity of the essential macrophage acetylcholine-mediated (cholinergic) receptor that responds to vagus nerve signals was previously unknown. Here we report that the nicotinic acetylcholine receptor alpha7 subunit is required for acetylcholine inhibition of macrophage TNF release. Electrical stimulation of the vagus nerve inhibits TNF synthesis in wild-type mice, but fails to inhibit TNF synthesis in alpha7-deficient mice. Thus, the nicotinic acetylcholine receptor alpha7 subunit is essential for inhibiting cytokine synthesis by the cholinergic anti-inflammatory pathway.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12508119     DOI: 10.1038/nature01339

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  1025 in total

1.  Stimulating the central nervous system to prevent intestinal dysfunction after traumatic brain injury.

Authors:  Vishal Bansal; Todd Costantini; Seok Yong Ryu; Carrie Peterson; William Loomis; James Putnam; Brian Elicieri; Andrew Baird; Raul Coimbra
Journal:  J Trauma       Date:  2010-05

Review 2.  Neutrophils in periodontal inflammation.

Authors:  David A Scott; Jennifer Krauss
Journal:  Front Oral Biol       Date:  2011-11-11

3.  X-linked cholestasis in mouse due to mutations of the P4-ATPase ATP11C.

Authors:  Owen M Siggs; Bernd Schnabl; Bill Webb; Bruce Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

Review 4.  The cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation.

Authors:  Valentin A Pavlov; Hong Wang; Christopher J Czura; Steven G Friedman; Kevin J Tracey
Journal:  Mol Med       Date:  2003 May-Aug       Impact factor: 6.354

5.  The North Shore-Long Island Jewish Research Institute.

Authors: 
Journal:  Mol Med       Date:  2003 Jan-Feb       Impact factor: 6.354

Review 6.  AKI and the Neuroimmune Axis.

Authors:  Shinji Tanaka; Mark D Okusa
Journal:  Semin Nephrol       Date:  2019-01       Impact factor: 5.299

7.  Progenitor cells: therapeutic targets after traumatic brain injury.

Authors:  Robert A Hetz; Supinder S Bedi; Scott Olson; Alex Olsen; Charles S Cox
Journal:  Transl Stroke Res       Date:  2012-05-22       Impact factor: 6.829

8.  Back-scattering interferometry: an ultrasensitive method for the unperturbed detection of acetylcholinesterase-inhibitor interactions.

Authors:  Gabrielle L Haddad; Sherri C Young; Ned D Heindel; Darryl J Bornhop; Robert A Flowers
Journal:  Angew Chem Int Ed Engl       Date:  2012-10-04       Impact factor: 15.336

9.  Cigarette smoke impairs cytokine responses and BCG containment in alveolar macrophages.

Authors:  Richard N van Zyl-Smit; Anke Binder; Richard Meldau; Patricia L Semple; Alicia Evans; Peter Smith; Eric D Bateman; Keertan Dheda
Journal:  Thorax       Date:  2013-11-28       Impact factor: 9.139

10.  Role of the nicotinic acetylcholine receptor α3 subtype in vascular inflammation.

Authors:  Cui Yang; Zhengtao Li; Saimei Yan; Yonghui He; Rong Dai; George Pek-Heng Leung; Shitian Pan; Jinyan Yang; Rong Yan; Guanhua Du
Journal:  Br J Pharmacol       Date:  2016-09-29       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.